FDA Accepts Vanda's BLA For Imsidolimab In Generalized Pustular Psoriasis

February 25, 2026 — 07:48 am EST

Written by RTTNews.com for RTTNews

(RTTNews) - Vanda Pharmaceuticals Inc. (VNDA) on Wednesday said the U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for imsidolimab for the treatment of Generalized Pustular Psoriasis (GPP), a rare autoinflammatory skin disorder.

A decision from the regulator is expected on December 12, 2026.

In the pivotal efficacy studies GEMINI-1 and GEMINI-2, a single intravenous dose of imsidolimab produced rapid disease clearance, with 53% of patients achieving clear or almost clear skin by Week 4, compared with 13% on placebo. Efficacy was sustained over approximately 2 years of monthly maintenance dosing, with no flares reported in the treatment arm. Imsidolimab demonstrated a favorable safety profile and a low incidence of anti-drug antibodies.

Vanda Pharmaceuticals shares closed at $8.17 on Tuesday, up 0.25%.

RTTNews

Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.

FDA Accepts Vanda's BLA For Imsidolimab In Generalized Pustular Psoriasis

Tags

Latest Articles